The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Escalating weekly fixed-dose of nimotuzumab in combination with concurrent chemoradiotherapy in patients with advanced esophageal cancer: A phase I study.
G. Jiang
No relevant relationships to disclose
K. Zhao
No relevant relationships to disclose
S. Yu
No relevant relationships to disclose
X. Chu
No relevant relationships to disclose
P. Liang
No relevant relationships to disclose
J. Zheng
No relevant relationships to disclose